We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Patient with Psoriasis and Vitiligo Treated with Etanercept.
- Authors
Campanati, Anna; Giuliodori, Katia; Ganzetti, Giulia; Liberati, Giulia; Offidani, Anna Maria
- Abstract
Psoriasis is a chronic, immune-mediated, inflammatory dermatosis whose aetiopathogenesis remains unclear, although tumour necrosis factor alpha (TNFα) appears to play a crucial role. The biological potential of TNFα inhibitors, such as etanercept, which reduce the inflammatory cascade, has radically changed the therapeutic management of patients with psoriasis and other immunomediated inflammatory diseases, associated with TNFα. The pathogenesis of the selective destruction of melanocytes in vitiligo is not fully understood, although there is growing evidence that several T helper type I cytokines, particularly TNFα, may be involved in the depigmentation process. A patient is described who presented with both psoriasis and vitiligo, and was treated with etanercept. After 24 weeks of therapy, the patient's psoriasis had improved markedly and the patient noted a mild improvement of vitiligo, with a reduction in macules and repigmentation in the scapular region.
- Subjects
PSORIASIS; VITILIGO; ETANERCEPT; INFLAMMATORY bowel diseases; SKIN diseases; TUMOR necrosis factors; PATIENTS
- Publication
American Journal of Clinical Dermatology, 2010, Vol 11, Issue S1, p46
- ISSN
1175-0561
- Publication type
Article
- DOI
10.2165/1153424-S0-000000000-00000